$MIRM
Mirum Pharmaceuticals, Inc.

2021 Q4 Form 10-Q Financial Statement

#000095017021004605 Filed on November 15, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q4
Revenue $3.138M $5.000M $0.00
YoY Change
Cost Of Revenue $1.903M
YoY Change
Gross Profit $1.235M
YoY Change
Gross Profit Margin 39.36%
Selling, General & Admin $19.04M $17.35M $7.230M
YoY Change 163.28% 202.84% 68.93%
% of Gross Profit 1541.3%
Research & Development $27.78M $30.47M $29.73M
YoY Change -6.58% 90.63% 106.75%
% of Gross Profit 2248.99%
Depreciation & Amortization $342.0K $84.00K $90.00K
YoY Change 280.0% 5.0% 50.0%
% of Gross Profit 27.69%
Operating Expenses $46.81M $47.82M $36.95M
YoY Change 26.68% 120.22% 98.02%
Operating Profit -$45.58M -$42.82M
YoY Change 97.2%
Interest Expense -$4.850M -$4.240M -$170.0K
YoY Change 2752.94% -1866.67% -123.29%
% of Operating Profit
Other Income/Expense, Net -$17.00K -$35.00K -$80.00K
YoY Change -78.75% 16.67%
Pretax Income $57.56M -$47.10M -$37.20M
YoY Change -254.73% 118.97% 107.47%
Income Tax $12.00K $9.000K $0.00
% Of Pretax Income 0.02%
Net Earnings $57.55M -$47.11M -$37.20M
YoY Change -254.69% 119.05% 107.24%
Net Earnings / Revenue 1833.84% -942.16%
Basic Earnings Per Share -$1.55
Diluted Earnings Per Share $1.884M -$1.551M -$1.425M
COMMON SHARES
Basic Shares Outstanding 30.64M 30.52M
Diluted Shares Outstanding 30.37M

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $156.5M $190.0M $231.8M
YoY Change -32.47% 42.08% 98.71%
Cash & Equivalents $31.34M $55.84M $142.1M
Short-Term Investments $125.2M $134.2M $89.73M
Other Short-Term Assets $5.271M $6.371M $4.500M
YoY Change 17.13% 44.8% 66.67%
Inventory $1.513M $0.00
Prepaid Expenses
Receivables $3.267M $400.0K $0.00
Other Receivables $0.00 $0.00
Total Short-Term Assets $166.6M $196.8M $236.4M
YoY Change -29.51% 42.41% 98.01%
LONG-TERM ASSETS
Property, Plant & Equipment $981.0K $1.060M $1.293M
YoY Change -24.13% -68.82% -5.76%
Goodwill
YoY Change
Intangibles $18.74M $19.00M $0.00
YoY Change
Long-Term Investments $4.983M $15.00M $0.00
YoY Change -100.0%
Other Assets $1.786M $1.641M $1.272M
YoY Change 40.41% 447.0% 292.59%
Total Long-Term Assets $128.1M $38.36M $4.514M
YoY Change 2736.93% 936.81% -83.49%
TOTAL ASSETS
Total Short-Term Assets $166.6M $196.8M $236.4M
Total Long-Term Assets $128.1M $38.36M $4.514M
Total Assets $294.7M $235.2M $240.9M
YoY Change 22.33% 65.73% 64.17%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $9.166M $5.003M $3.151M
YoY Change 190.89% -3.79% -5.97%
Accrued Expenses $30.72M $43.85M $13.41M
YoY Change 129.09% 222.4% 43.77%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $42.60M $50.39M $18.46M
YoY Change 130.72% 168.02% 41.19%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $17.00K $19.00K $29.00K
YoY Change -41.38% -99.32% -19.44%
Total Long-Term Liabilities $17.00K $19.00K $29.00K
YoY Change -41.38% -99.32% -19.44%
TOTAL LIABILITIES
Total Short-Term Liabilities $42.60M $50.39M $18.46M
Total Long-Term Liabilities $17.00K $19.00K $29.00K
Total Liabilities $174.4M $178.8M $68.77M
YoY Change 153.66% 727.64% 320.27%
SHAREHOLDERS EQUITY
Retained Earnings -$257.2M -$314.7M -$173.2M
YoY Change 48.5% 147.74%
Common Stock $377.4M $371.1M $345.2M
YoY Change 9.34% 72.49%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $120.2M $56.40M $172.1M
YoY Change
Total Liabilities & Shareholders Equity $294.7M $235.2M $240.9M
YoY Change 22.33% 65.73% 64.17%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q4
OPERATING ACTIVITIES
Net Income $57.55M -$47.11M -$37.20M
YoY Change -254.69% 119.05% 107.24%
Depreciation, Depletion And Amortization $342.0K $84.00K $90.00K
YoY Change 280.0% 5.0% 50.0%
Cash From Operating Activities -$33.15M -$34.20M -$36.28M
YoY Change -8.64% 96.0% 164.82%
INVESTING ACTIVITIES
Capital Expenditures -$19.00M -$18.00K -$30.00K
YoY Change 63243.33% -64.0% -57.14%
Acquisitions
YoY Change
Other Investing Activities $127.0M -$2.219M -$4.920M
YoY Change -2681.83% -88.24% -3.15%
Cash From Investing Activities $108.0M -$2.237M -$4.950M
YoY Change -2282.28% -88.17% -3.7%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 615.0K 345.0K 134.5M
YoY Change -99.54% -83.57%
NET CHANGE
Cash From Operating Activities -33.15M -34.20M -36.28M
Cash From Investing Activities 108.0M -2.237M -4.950M
Cash From Financing Activities 615.0K 345.0K 134.5M
Net Change In Cash 75.49M -36.09M 93.28M
YoY Change -19.07% 5.35% -595.12%
FREE CASH FLOW
Cash From Operating Activities -$33.15M -$34.20M -$36.28M
Capital Expenditures -$19.00M -$18.00K -$30.00K
Free Cash Flow -$14.14M -$34.18M -$36.25M
YoY Change -60.98% 96.46% 165.96%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
mirm Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
mirm Accrued Milestone Payments Classified As Intangible Assets Net
AccruedMilestonePaymentsClassifiedAsIntangibleAssetsNet
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases Sales Issuances Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements
CY2020Q4 us-gaap Assets Current
AssetsCurrent
236350000
mirm Non Cash Interest Expense On Revenue Interest Purchase Agreement
NonCashInterestExpenseOnRevenueInterestPurchaseAgreement
dei Amendment Flag
AmendmentFlag
false
us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseMember
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseMember
mirm Proceeds Of Issuance Costs Related To The Revenue Interest Liability
ProceedsOfIssuanceCostsRelatedToTheRevenueInterestLiability
dei Entity Central Index Key
EntityCentralIndexKey
0001759425
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseMember
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38981
dei Entity Registrant Name
EntityRegistrantName
Mirum Pharmaceuticals, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
83-1281555
dei Entity Address Address Line1
EntityAddressAddressLine1
950 Tower Lane, Suite 1050,
dei Entity Address City Or Town
EntityAddressCityOrTown
Foster City
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94404
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
667-4085
dei Security12b Title
Security12bTitle
Common stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
MIRM
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
30638194
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
55844000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
142086000
CY2021Q3 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
400000
CY2020Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
0
CY2021Q3 us-gaap Short Term Investments
ShortTermInvestments
134190000
CY2021Q3 mirm Revenue Interest Liability Noncurrent
RevenueInterestLiabilityNoncurrent
126277000
CY2020Q4 mirm Revenue Interest Liability Noncurrent
RevenueInterestLiabilityNoncurrent
47651000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1293000
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1664000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1949000
CY2021Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
19000000
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
0
CY2020Q4 us-gaap Short Term Investments
ShortTermInvestments
89734000
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6371000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4530000
CY2021Q3 us-gaap Assets Current
AssetsCurrent
196805000
CY2021Q3 us-gaap Long Term Investments
LongTermInvestments
14997000
CY2020Q4 us-gaap Long Term Investments
LongTermInvestments
0
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1060000
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1641000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1272000
CY2021Q3 us-gaap Assets
Assets
235167000
CY2020Q4 us-gaap Assets
Assets
240864000
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
5003000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3151000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
43847000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
13411000
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
690000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
636000
CY2021Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
847000
CY2020Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
1264000
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
50387000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
18462000
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2088000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2627000
CY2021Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
19000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
29000
CY2021Q3 us-gaap Liabilities
Liabilities
178771000
CY2020Q4 us-gaap Liabilities
Liabilities
68769000
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-314705000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-173171000
CY2021Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-6000
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
30562167
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
30406303
CY2021Q3 mirm Common Stock Shares Outstanding Subject To Repurchase
CommonStockSharesOutstandingSubjectToRepurchase
155864
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
30032600
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29776544
CY2020Q4 mirm Common Stock Shares Outstanding Subject To Repurchase
CommonStockSharesOutstandingSubjectToRepurchase
256056
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
3000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
3000
CY2021Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
371104000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
345180000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
83000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
56396000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
172095000
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
235167000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
240864000
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5000000
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
16000000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2021Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
30471000
CY2020Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
15984000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
103653000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
51879000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17353000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5732000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
40185000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15466000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
47824000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
21716000
us-gaap Operating Expenses
OperatingExpenses
143838000
us-gaap Operating Expenses
OperatingExpenses
67345000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-42824000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-21716000
us-gaap Operating Income Loss
OperatingIncomeLoss
-127838000
us-gaap Operating Income Loss
OperatingIncomeLoss
-67345000
CY2021Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
72000
CY2020Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
237000
us-gaap Investment Income Interest
InvestmentIncomeInterest
301000
us-gaap Investment Income Interest
InvestmentIncomeInterest
1391000
CY2021Q3 mirm Other Nonoperating Interest Expense
OtherNonoperatingInterestExpense
5667000
CY2020Q3 mirm Other Nonoperating Interest Expense
OtherNonoperatingInterestExpense
0
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
295000
CY2021Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
643000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4823000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-43894000
CY2021Q2 us-gaap Other Comprehensive Income Loss Before Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
-13000
mirm Other Nonoperating Interest Expense
OtherNonoperatingInterestExpense
13824000
mirm Other Nonoperating Interest Expense
OtherNonoperatingInterestExpense
0
CY2021Q3 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Issues
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues
-1355000
CY2020Q3 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Issues
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues
0
us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Issues
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues
-417000
us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Issues
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues
0
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-35000
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-30000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-565000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-109000
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-47099000
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-21509000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-141509000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-66063000
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
9000
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-3000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
25000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-47108000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-21506000
us-gaap Net Income Loss
NetIncomeLoss
-141534000
us-gaap Net Income Loss
NetIncomeLoss
-66067000
CY2021Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.55
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.86
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.68
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.65
CY2021Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
30367727
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
25132916
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
30250127
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
24965178
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-47108000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-21506000
us-gaap Net Income Loss
NetIncomeLoss
-141534000
us-gaap Net Income Loss
NetIncomeLoss
-66067000
CY2021Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
7000
CY2020Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-151000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-83000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
39000
CY2021Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
0
CY2020Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
5000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-6000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-4000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-47101000
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-21652000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-141623000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-66024000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
172095000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
95737000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
345000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7415000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
80000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5285000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-50532000
CY2021Q1 us-gaap Other Comprehensive Income Loss Before Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
-83000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
133883000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-47108000
CY2021Q3 us-gaap Other Comprehensive Income Loss Before Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
7000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
56396000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
130349000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2573000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-21310000
CY2020Q1 us-gaap Other Comprehensive Income Loss Before Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
-153000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
156118000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
25000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2974000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-23251000
CY2020Q2 us-gaap Other Comprehensive Income Loss Before Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
342000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
136208000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
27000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3428000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-21506000
CY2020Q3 us-gaap Other Comprehensive Income Loss Before Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
-146000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
120255000
us-gaap Profit Loss
ProfitLoss
-141534000
us-gaap Profit Loss
ProfitLoss
-66067000
us-gaap Share Based Compensation
ShareBasedCompensation
17523000
us-gaap Share Based Compensation
ShareBasedCompensation
8975000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
253000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
220000
mirm Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
285000
mirm Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
238000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
80000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-32000
mirm Non Cash Interest Expense On Revenue Interest Purchase Agreement
NonCashInterestExpenseOnRevenueInterestPurchaseAgreement
13824000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases Sales Issuances Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements
417000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2241000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1699000
mirm Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-94000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
374000
mirm Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities
IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities
13635000
mirm Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities
IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities
5655000
mirm Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-485000
mirm Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-244000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-99611000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-52796000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
117600000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
71400000
mirm Proceeds From Paydowns Of Investments
ProceedsFromPaydownsOfInvestments
2000000
mirm Proceeds From Paydowns Of Investments
ProceedsFromPaydownsOfInvestments
23608000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
179055000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
51991000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
21000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
197000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-59476000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
42820000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
6914000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
46903000
mirm Proceeds Of Issuance Costs Related To The Revenue Interest Liability
ProceedsOfIssuanceCostsRelatedToTheRevenueInterestLiability
64574000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
1363000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
52000
us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
175000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
72851000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
46780000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-6000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
4000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-86242000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
36808000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
142086000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
11970000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
55844000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
48778000
us-gaap Operating Lease Payments
OperatingLeasePayments
645000
us-gaap Operating Lease Payments
OperatingLeasePayments
362000
mirm Accrued Milestone Payments Classified As Intangible Assets Net
AccruedMilestonePaymentsClassifiedAsIntangibleAssetsNet
19000000
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2018-05-02
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-314700000
CY2021Q3 mirm Cash Cash Equivalents And Short And Long Term Investments
CashCashEquivalentsAndShortAndLongTermInvestments
205000000.0
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">preparation of consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the financial statements and accompanying notes. The most significant estimates in the Company’s unaudited condensed consolidated financial statements relate to the revenue interest liability, accrued research and development expenses, the valuation of derivative liabilities, equity award compensation and the valuation allowance of deferred tax assets resulting from net operating losses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">estimates and assumptions are based upon historical experience, knowledge of current events and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results could differ materially from those estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P11Y
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7354161
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5903227
CY2021Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
134190000
CY2021Q3 mirm Cash Equivalents And Available For Sale Debt Securities Amortized Cost Basis
CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
201698000
CY2021Q3 mirm Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2021Q3 mirm Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
2000
CY2021Q3 mirm Cash Equivalents And Available For Sale Securities Debt Securities
CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities
201696000
CY2021Q3 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
52509000
CY2021Q3 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
14997000
CY2021Q3 mirm Cash Equivalents And Available For Sale Securities Debt Securities
CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities
201696000
CY2020Q4 mirm Cash Equivalents And Available For Sale Debt Securities Amortized Cost Basis
CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
229432000
CY2020Q4 mirm Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
82000
CY2020Q4 mirm Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1000
CY2020Q4 mirm Cash Equivalents And Available For Sale Securities Debt Securities
CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities
229513000
CY2020Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
139779000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
89734000
CY2020Q4 mirm Cash Equivalents And Available For Sale Securities Debt Securities
CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities
229513000
CY2021Q3 us-gaap Available For Sale Securities Debt Maturities Next Rolling Twelve Months Fair Value
AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue
134190000
CY2021Q3 mirm Held To Maturity Securities Debt Maturities Rolling Year One Through Two Fair Value
HeldToMaturitySecuritiesDebtMaturitiesRollingYearOneThroughTwoFairValue
14997000
CY2021Q3 us-gaap Held To Maturity Securities Fair Value
HeldToMaturitySecuritiesFairValue
149187000
CY2021Q3 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2020Q3 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2021Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
0
CY2020Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
0
us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
0
us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
0
CY2021Q1 mirm Revenue Interest Liability
RevenueInterestLiability
50860000
CY2021Q3 mirm Accrued Clinical Trials Current
AccruedClinicalTrialsCurrent
6026000
CY2020Q4 mirm Accrued Clinical Trials Current
AccruedClinicalTrialsCurrent
3673000
CY2021Q3 mirm Accrued Milestones Current
AccruedMilestonesCurrent
19000000
CY2020Q4 mirm Accrued Milestones Current
AccruedMilestonesCurrent
0
CY2021Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
4462000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2157000
CY2021Q3 mirm Accrued Contract Manufacturing And Non Clinical Costs Current
AccruedContractManufacturingAndNonClinicalCostsCurrent
7644000
CY2020Q4 mirm Accrued Contract Manufacturing And Non Clinical Costs Current
AccruedContractManufacturingAndNonClinicalCostsCurrent
2780000
CY2021Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6715000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4801000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
43847000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
13411000
CY2020Q4 mirm Revenue Interest Liability
RevenueInterestLiability
47651000
CY2021Q1 mirm Interest Expense Accrued
InterestExpenseAccrued
3381000
CY2021Q1 mirm Debt Issuances Costs Capitalized
DebtIssuancesCostsCapitalized
172000
CY2019Q1 us-gaap Area Of Land
AreaOfLand
5600
us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
The lease term is approximately four years with an option to extend the term for one five-year term, which at the time was not reasonably assured of exercise and therefore, not included in the lease term.
CY2019Q1 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P4Y
CY2019Q1 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2019Q1 mirm Tenant Improvement Allowance
TenantImprovementAllowance
400000
CY2021Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.080
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1700000
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
2800000
CY2021Q2 us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
65000000
CY2021Q2 mirm Interest Expense Accrued
InterestExpenseAccrued
4776000
CY2021Q2 mirm Debt Issuances Costs Capitalized
DebtIssuancesCostsCapitalized
26000
CY2021Q2 mirm Revenue Interest Liability
RevenueInterestLiability
120610000
CY2021Q3 mirm Interest Expense Accrued
InterestExpenseAccrued
5667000
CY2021Q3 mirm Revenue Interest Liability
RevenueInterestLiability
126277000
CY2021Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y4M24D
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
219000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
888000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
916000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
925000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
230000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
3178000
CY2021Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
400000
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
2778000
CY2021Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
200000
CY2020Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
200000
us-gaap Operating Lease Expense
OperatingLeaseExpense
500000
us-gaap Operating Lease Expense
OperatingLeaseExpense
500000
CY2020Q3 mirm Maximum Amount Of Sale Covered In Shelf Registration Statement
MaximumAmountOfSaleCoveredInShelfRegistrationStatement
300000000.0
CY2021Q3 mirm Common Stock Aggregate Offering Price Remaining
CommonStockAggregateOfferingPriceRemaining
68400000
CY2021Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
9429216
CY2020Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
8343673
us-gaap Share Based Goods And Nonemployee Services Transaction Modification Of Terms Incremental Compensation Cost
ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost
600000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7415000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3428000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
17523000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8975000

Files In Submission

Name View Source Status
0000950170-21-004605-index-headers.html Edgar Link pending
0000950170-21-004605-index.html Edgar Link pending
0000950170-21-004605.txt Edgar Link pending
0000950170-21-004605-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
mirm-20210930.htm Edgar Link pending
mirm-20210930.xsd Edgar Link pending
mirm-20210930_cal.xml Edgar Link unprocessable
mirm-20210930_def.xml Edgar Link unprocessable
mirm-20210930_htm.xml Edgar Link completed
mirm-20210930_lab.xml Edgar Link unprocessable
mirm-20210930_pre.xml Edgar Link unprocessable
mirm-ex31_1.htm Edgar Link pending
mirm-ex31_2.htm Edgar Link pending
mirm-ex32_1.htm Edgar Link pending
mirm-ex32_2.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending